At NanoDetection Technology™, our Human Diagnostics Pipeline is dedicated to the development of rapid, accurate, and cost-effective diagnostic solutions for infectious diseases and emerging public health threats. Utilizing proprietary antibody technologies, advanced biomarker detection platforms, and next-generation chemiluminescent and lateral flow assay systems, NDT is advancing diagnostic programs targeting Methicillin-Resistant Staphylococcus aureus (MRSA), Methicillin-Susceptible Staphylococcus aureus (MSSA), Highly Pathogenic Avian Influenza (HPAI), and a growing portfolio of emerging infectious diseases.

Our mission is to provide healthcare providers, laboratories, and public health agencies with fast, reliable tools that enable earlier detection, improved surveillance, and timely treatment decisions. By combining laboratory-quality performance with scalable point-of-care and field-deployable platforms, NDT is positioned to support global efforts in infectious disease control, outbreak response, antimicrobial stewardship, and pandemic preparedness.